[1]
Hair and Scalp Changes in Cutaneous and Systemic Lupus Erythematosus., Udompanich S,Chanprapaph K,Suchonwanit P,, American journal of clinical dermatology, 2018 Jun 9
[PubMed PMID: 29948959]
[2]
Dammacco R,Procaccio P,Racanelli V,Vacca A,Dammacco F, Ocular Involvement in Systemic Lupus Erythematosus: The Experience of Two Tertiary Referral Centers. Ocular immunology and inflammation. 2018 Aug 10
[PubMed PMID: 30096011]
[3]
Abadías-Granado I,Sánchez-Bernal J,Felipo-Berlanga F,Ara-Martín M, Coexistence of Tumid Lupus Erythematosus and Discoid Lupus Erythematosus. Actas dermo-sifiliograficas. 2018 Jul 30
[PubMed PMID: 30072022]
[4]
Sontheimer RD, The lexicon of cutaneous lupus erythematosus--a review and personal perspective on the nomenclature and classification of the cutaneous manifestations of lupus erythematosus. Lupus. 1997
[PubMed PMID: 9061656]
Level 3 (low-level) evidence
[5]
Salah E, Clinical and dermoscopic spectrum of discoid lupus erythematosus: novel observations from lips and oral mucosa. International journal of dermatology. 2018 Jul
[PubMed PMID: 29700807]
[6]
Drenkard C,Parker S,Aspey LD,Gordon C,Helmick CG,Bao G,Lim SS, Racial Disparities in the Incidence of Primary Chronic Cutaneous Lupus Erythematosus in the Southeastern United States: The Georgia Lupus Registry. Arthritis care
[PubMed PMID: 29669194]
[7]
[Epidemiology of systemic lupus erythematosus in Reunion Island, Indian Ocean: A case-series in adult patients from a University Hospital]., Gaüzère L,Gerber A,Renou F,Ferrandiz D,Bagny K,Osdoit S,Yvin JL,Raffray L,, La Revue de medecine interne, 2018 Jul 21
[PubMed PMID: 30041816]
Level 3 (low-level) evidence
[8]
Oh EH,Kim EJ,Ro YS,Ko JY, Ten-year retrospective clinicohistological study of cutaneous lupus erythematosus in Korea. The Journal of dermatology. 2018 Apr
[PubMed PMID: 29423919]
Level 2 (mid-level) evidence
[9]
Kahn JS,Deverapalli SC,Rosmarin DM, JAK-STAT signaling pathway inhibition: a role for treatment of discoid lupus erythematosus and dermatomyositis. International journal of dermatology. 2018 Aug
[PubMed PMID: 29873082]
[10]
Two A,So JK,Paravar T, Discoid Lupus and Human Immunodeficiency Virus: A Retrospective Chart Review to Determine the Prevalence and Progression of Co-occurrence of these Conditions at a Single Academic Center. Indian journal of dermatology. 2017 Mar-Apr
[PubMed PMID: 28400654]
Level 2 (mid-level) evidence
[12]
Mutasim DF,Adams BB, Immunofluorescence in dermatology. Journal of the American Academy of Dermatology. 2001 Dec
[PubMed PMID: 11712024]
[13]
Dahl MV, Usefulness of direct immunofluorescence in patients with lupus erythematosus. Archives of dermatology. 1983 Dec;
[PubMed PMID: 6360051]
[14]
Harrist TJ,Mihm MC Jr, The specificity and clinical usefulness of the lupus band test. Arthritis and rheumatism. 1980 Apr;
[PubMed PMID: 6989372]
[15]
George R,Kurian S,Jacob M,Thomas K, Diagnostic evaluation of the lupus band test in discoid and systemic lupus erythematosus. International journal of dermatology. 1995 Mar
[PubMed PMID: 7751090]
[16]
Chong BF,Song J,Olsen NJ, Determining risk factors for developing systemic lupus erythematosus in patients with discoid lupus erythematosus. The British journal of dermatology. 2012 Jan
[PubMed PMID: 21910708]
[17]
Inamadar AC, Perforation of paper with pen: Simple technique to explain the carpet tack sign in discoid lupus erythematosus. Journal of the American Academy of Dermatology. 2019 Dec
[PubMed PMID: 30905795]
[18]
Rowell NR, Laboratory abnormalities in the diagnosis and management of lupus erythematosus. The British journal of dermatology. 1971 Mar;
[PubMed PMID: 4102091]
[19]
Zaalberg A,Moradi Tuchayi S,Ameri AH,Ngo KH,Cunningham TJ,Eliane JP,Livneh M,Horn TD,Rosman IS,Musiek A,Anadkat MJ,Demehri S, Chronic Inflammation Promotes Skin Carcinogenesis in Cancer-Prone Discoid Lupus Erythematosus. The Journal of investigative dermatology. 2019 Jan;
[PubMed PMID: 30030152]
[20]
Farley-Loftus R,Elmariah SB,Ralston J,Kamino H,Franks AG Jr, Hypertrophic discoid lupus erythematosus. Dermatology online journal. 2010 Nov 15
[PubMed PMID: 21163152]
[21]
Flynn A,Gilhooley E,O'Shea F,Wynne B, The use of SLICC and ACR criteria to correctly label patients with cutaneous lupus and systemic lupus erythematosus. Clinical rheumatology. 2018 Mar
[PubMed PMID: 29392510]
[22]
Xie HH,Shen H,Zhang L,Cui MY,Xia LP,Lu J, Elevated Serum Interleukin-34 Level in Patients with Systemic Lupus Erythematosus Is Associated with Disease Activity. Scientific reports. 2018 Feb 22
[PubMed PMID: 29472590]
[23]
Kretz CC,Norpo M,Abeler-Dörner L,Linke B,Haust M,Edler L,Krammer PH,Kuhn A, Anti-annexin 1 antibodies: a new diagnostic marker in the serum of patients with discoid lupus erythematosus. Experimental dermatology. 2010 Oct
[PubMed PMID: 20701627]
[24]
Callen JP, Discoid lupus erythematosus--variants and clinical associations. Clinics in dermatology. 1985 Jul-Sep
[PubMed PMID: 3880023]
[25]
Muangchan C,van Vollenhoven RF,Bernatsky SR,Smith CD,Hudson M,Inanç M,Rothfield NF,Nash PT,Furie RA,Senécal JL,Chandran V,Burgos-Vargas R,Ramsey-Goldman R,Pope JE, Treatment Algorithms in Systemic Lupus Erythematosus. Arthritis care
[PubMed PMID: 25777803]
[26]
Powers DB, Systemic lupus erythematosus and discoid lupus erythematosus. Oral and maxillofacial surgery clinics of North America. 2008 Nov
[PubMed PMID: 18940631]
[27]
Francès C,Barète S,Piette JC, [Dermatologic manifestations in lupus erythematosus]. La Revue de medecine interne. 2008 Sep
[PubMed PMID: 18562046]
[28]
Bjornberg A,Hellgren L, Topical treatment of chronic discoid lupus erythematosus with betamethason-17-valerate and fluocinolone acetonie-a double blind study. Indian journal of dermatology. 1966 Oct;
[PubMed PMID: 5341750]
Level 1 (high-level) evidence
[29]
Jessop S,Whitelaw DA,Delamere FM, Drugs for discoid lupus erythematosus. The Cochrane database of systematic reviews. 2009 Oct 7
[PubMed PMID: 19821298]
Level 1 (high-level) evidence
[30]
Tzellos TG,Kouvelas D, Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation. European journal of clinical pharmacology. 2008 Apr
[PubMed PMID: 18157526]
[31]
Sárdy M,Ruzicka T,Kuhn A, Topical calcineurin inhibitors in cutaneous lupus erythematosus. Archives of dermatological research. 2009 Jan
[PubMed PMID: 18797893]
[32]
Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF, American Academy of Ophthalmology. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology. 2016 Jun:123(6):1386-94. doi: 10.1016/j.ophtha.2016.01.058. Epub 2016 Mar 16
[PubMed PMID: 26992838]
[33]
Cavazzana I,Sala R,Bazzani C,Ceribelli A,Zane C,Cattaneo R,Tincani A,Calzavara-Pinton PG,Franceschini F, Treatment of lupus skin involvement with quinacrine and hydroxychloroquine. Lupus. 2009 Jul;
[PubMed PMID: 19502270]
[34]
Seiger E,Roland S,Goldman S, Cutaneous lupus treated with topical tretinoin: a case report. Cutis. 1991 May
[PubMed PMID: 2070657]
Level 3 (low-level) evidence
[35]
Kuhn A,Ruland V,Bonsmann G, Cutaneous lupus erythematosus: update of therapeutic options part II. Journal of the American Academy of Dermatology. 2011 Dec
[PubMed PMID: 20800319]
[36]
Wenzel J,Brähler S,Bauer R,Bieber T,Tüting T, Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. The British journal of dermatology. 2005 Jul
[PubMed PMID: 16029342]
Level 2 (mid-level) evidence
[37]
Ortiz Z,Shea B,Suarez-Almazor ME,Moher D,Wells GA,Tugwell P, The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. The Journal of rheumatology. 1998 Jan;
[PubMed PMID: 9458200]
Level 1 (high-level) evidence
[38]
Pelle MT,Werth VP, Thalidomide in cutaneous lupus erythematosus. American journal of clinical dermatology. 2003;
[PubMed PMID: 12762830]
[39]
Chasset F,Tounsi T,Cesbron E,Barbaud A,Francès C,Arnaud L, Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: A systematic review and meta-analysis. Journal of the American Academy of Dermatology. 2018 Feb
[PubMed PMID: 28989111]
Level 1 (high-level) evidence
[40]
Généreau T,Chosidow O,Danel C,Chérin P,Herson S, High-dose intravenous immunoglobulin in cutaneous lupus erythematosus. Archives of dermatology. 1999 Sep
[PubMed PMID: 10490126]
[41]
Chen P,Broadbent E,Coomarasamy C,Jarrett P, Illness perception in association with psychological functioning in patients with discoid lupus erythematosus. The British journal of dermatology. 2015 Sep
[PubMed PMID: 25639859]
[42]
Kuhn A,Sonntag M,Richter-Hintz D,Oslislo C,Megahed M,Ruzicka T,Lehmann P, Phototesting in lupus erythematosus: a 15-year experience. Journal of the American Academy of Dermatology. 2001 Jul;
[PubMed PMID: 11423840]
[43]
Wozniacka A,Carter A,McCauliffe DP, Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit. Lupus. 2002
[PubMed PMID: 11958581]
[44]
Cusack C,Danby C,Fallon JC,Ho WL,Murray B,Brady J,O'Kelly P,Ambrose N,Kearns G,Murphy GM, Photoprotective behaviour and sunscreen use: impact on vitamin D levels in cutaneous lupus erythematosus. Photodermatology, photoimmunology & photomedicine. 2008 Oct
[PubMed PMID: 18811868]
[45]
Kuhn A,Landmann A,Wenzel J, Advances in the treatment of cutaneous lupus erythematosus. Lupus. 2016 Jul
[PubMed PMID: 27252259]
Level 3 (low-level) evidence
[47]
Jessop S,Whitelaw DA,Grainge MJ,Jayasekera P, Drugs for discoid lupus erythematosus. The Cochrane database of systematic reviews. 2017 May 5
[PubMed PMID: 28476075]
Level 1 (high-level) evidence
[48]
Drucker AM,Su J,Mussani F,Siddha SK,Gladman DD,Urowitz MB, Prognostic implications of active discoid lupus erythematosus and malar rash at the time of diagnosis of systemic lupus erythematosus: Results from a prospective cohort study. Lupus. 2016 Apr
[PubMed PMID: 26453664]